Revolutionizing Gene Therapy Manufacturing: Viralgen’s Pro10™ Cells Boost Efficiency and Scalability of rAAV Production

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

The Pro10™ cell line is a new technology that has been designed to enhance the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology allows for the scalable and robust production of rAAVs, addressing the challenges associated with large-scale manufacturing in AAV gene therapies.

Viralgen utilizes the Pro10™ cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been specifically optimized for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes. The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors and have significantly contributed to the production of innovative gene therapies.

For more information on this animal component-free suspension Pro10™ cell line, access the full PDF detailing its HEK293 derived origins. This can help reduce process development time and costs, making it an attractive option for biopharmaceutical companies looking to streamline their gene therapy development processes.

Leave a Reply